[go: up one dir, main page]

DK1194528T3 - Monoklonalt antistof mod faktor VII, hvilket antistof selv ved forekomst i molært overskud kun delvist inaktiverer faktor VII, samt fremgangsmåde til produktion af et sådant antistof - Google Patents

Monoklonalt antistof mod faktor VII, hvilket antistof selv ved forekomst i molært overskud kun delvist inaktiverer faktor VII, samt fremgangsmåde til produktion af et sådant antistof

Info

Publication number
DK1194528T3
DK1194528T3 DK00949329T DK00949329T DK1194528T3 DK 1194528 T3 DK1194528 T3 DK 1194528T3 DK 00949329 T DK00949329 T DK 00949329T DK 00949329 T DK00949329 T DK 00949329T DK 1194528 T3 DK1194528 T3 DK 1194528T3
Authority
DK
Denmark
Prior art keywords
ligands
factor
molar excess
factor viii
complex
Prior art date
Application number
DK00949329T
Other languages
Danish (da)
English (en)
Inventor
Marc G Jacquemin
Jean-Marie R Saint-Remy
Original Assignee
D Collen Res Foundation Vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9916450.1A external-priority patent/GB9916450D0/en
Application filed by D Collen Res Foundation Vzw filed Critical D Collen Res Foundation Vzw
Application granted granted Critical
Publication of DK1194528T3 publication Critical patent/DK1194528T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK00949329T 1999-07-14 2000-07-13 Monoklonalt antistof mod faktor VII, hvilket antistof selv ved forekomst i molært overskud kun delvist inaktiverer faktor VII, samt fremgangsmåde til produktion af et sådant antistof DK1194528T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14389199P 1999-07-14 1999-07-14
GBGB9916450.1A GB9916450D0 (en) 1999-07-14 1999-07-14 Ligands for use in therapeutic compounds for the treatment of hemostasis disorders
PCT/EP2000/006677 WO2001004269A1 (fr) 1999-07-14 2000-07-13 Ligands destines a etre utilises dans des compositions therapeutiques pour le traitement d'affections hemostatiques

Publications (1)

Publication Number Publication Date
DK1194528T3 true DK1194528T3 (da) 2007-07-09

Family

ID=26315767

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00949329T DK1194528T3 (da) 1999-07-14 2000-07-13 Monoklonalt antistof mod faktor VII, hvilket antistof selv ved forekomst i molært overskud kun delvist inaktiverer faktor VII, samt fremgangsmåde til produktion af et sådant antistof

Country Status (11)

Country Link
EP (1) EP1194528B1 (fr)
JP (2) JP4297207B2 (fr)
AT (1) ATE356201T1 (fr)
AU (1) AU781638B2 (fr)
CA (1) CA2381125C (fr)
CY (1) CY1107638T1 (fr)
DE (1) DE60033814T2 (fr)
DK (1) DK1194528T3 (fr)
ES (1) ES2283308T3 (fr)
PT (1) PT1194528E (fr)
WO (1) WO2001004269A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829085B2 (en) 1999-07-14 2010-11-09 Life Sciences Research Partners Vzw Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII
PT1222929E (pt) 2001-01-11 2010-08-18 Life Sciences Res Partners Vzw Método e composição farmacêutica para prevenir e/ou tratar síndrome da resposta inflamatória sistémica
KR100925348B1 (ko) 2001-06-12 2009-11-09 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 인간형 항-혈액 응고 인자 ⅷ 항체
EP1388544A1 (fr) 2002-07-31 2004-02-11 D. Collen Research Foundation vzw Anticorps anti-idiotypes dirigés contre l'inhibiteur de facteur VIII et leurs applications
JP4422430B2 (ja) 2003-05-14 2010-02-24 帝國製薬株式会社 エストロゲン及び／又はプロゲストゲン含有外用貼付剤
EP1706079B1 (fr) 2003-08-14 2013-02-20 ThromboGenics N.V. Anticorps spécifique pour le facteur viii modifiée par glycosylation dans la région variable
EP1791557A4 (fr) 2004-09-07 2009-09-23 Archemix Corp Chimie medicale utilisant des aptameres
US7566701B2 (en) 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
CA2616902A1 (fr) * 2005-07-29 2007-02-15 Life Sciences Research Partners Vzw Nouveaux anticorps anti-facteur viii
FR2892724B1 (fr) 2005-11-02 2008-01-04 Lab Francais Du Fractionnement Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
FR2897868B1 (fr) * 2006-02-24 2012-08-31 Lab Francais Du Fractionnement Anticorps anti-idiotypiques neutralisant l'activite inhibitrice d'un anticorps inhibiteur dirige contre le domaine c1 du facteur viii.
EP2451835A1 (fr) 2009-07-10 2012-05-16 ThromboGenics N.V. Variantes du plasminogène et de la plasmine
WO2011023805A1 (fr) 2009-08-28 2011-03-03 Thrombogenics N.V. Utilisation de plasmine pour le traitement d'une insuffisance de filtration après une trabéculectomie
ES2583082T3 (es) 2011-01-05 2016-09-19 Thrombogenics N.V. Variantes de plasminógeno y plasmina
WO2013024074A1 (fr) 2011-08-12 2013-02-21 Thrombogenics N.V. Variants du plasminogène et de la plasmine
ES2628321T3 (es) 2011-12-01 2017-08-02 Thrombogenics N.V. Mejora del resultado de una trabeculectomía
KR101395736B1 (ko) * 2012-07-10 2014-05-16 아주대학교산학협력단 인간 혈액응고인자 ⅷ 도메인 특이적 항체 및 이의 제조방법
WO2017153567A1 (fr) 2016-03-10 2017-09-14 Thrombogenics Nv Inhibition postérieure de la fibrose oculaire par antagonisation du facteur de croissance placentaire
WO2018206734A1 (fr) * 2017-05-11 2018-11-15 Vib Vzw Glycosylation de domaines variables d'immunoglobuline

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose

Also Published As

Publication number Publication date
CA2381125A1 (fr) 2001-01-18
ATE356201T1 (de) 2007-03-15
PT1194528E (pt) 2007-05-31
AU781638B2 (en) 2005-06-02
ES2283308T3 (es) 2007-11-01
JP2008295455A (ja) 2008-12-11
AU6273000A (en) 2001-01-30
EP1194528A1 (fr) 2002-04-10
DE60033814D1 (de) 2007-04-19
DE60033814T2 (de) 2007-11-08
CA2381125C (fr) 2013-04-23
JP2003504045A (ja) 2003-02-04
WO2001004269A1 (fr) 2001-01-18
EP1194528B1 (fr) 2007-03-07
JP4297207B2 (ja) 2009-07-15
CY1107638T1 (el) 2013-04-18
JP4297225B2 (ja) 2009-07-15

Similar Documents

Publication Publication Date Title
DK1194528T3 (da) Monoklonalt antistof mod faktor VII, hvilket antistof selv ved forekomst i molært overskud kun delvist inaktiverer faktor VII, samt fremgangsmåde til produktion af et sådant antistof
ATE493148T1 (de) Antikörper zur hemmung der blutgerinnung und anwendungsverfahren dafür
ATE540976T1 (de) Antikörper zur inhibierung der blutgerinnung und verfahren zur deren verwendung
DE69932084D1 (de) Antikörperfragmente zur lokalen Behandlung von Augenerkrankungen
DE602004031390D1 (de) Gerinnungsfaktor VII-Fc chimäre Proteine zur Behandlung von hämostatischen Krankheiten
WO2002060955A3 (fr) Anticorps modifies et procedes d'utilisation
ATE434447T1 (de) Zusammensetzungen und verfahren zur erzeugung von gefässeokklusion
CY1108566T1 (el) Ανοσολογικος ελεγχος των επιπεδων του b-αμυλοειδους in vivo
PT833911E (pt) Anticorpos anti-factor tecidular enxertados com cdr e metodos para a sua utilizacao
HK1080372A1 (zh) 作为抗凝剂的新型组织因子目标抗体
WO1999008109A3 (fr) Anticorps diriges contre des epitopes specifiques a l'oxydation sur lipoproteines et leurs procedes d'utilisation dans la detection, le suivi et l'inhibition de la croissance d'atheromes
CN109153726A (zh) 抗因子xi的活性位点的单克隆抗体及其用途
CA2368670A1 (fr) Modulation de la permeabilite vasculaire au moyen d'activateurs de recepteurs tie2
PT1214600E (pt) Determinacao de proteinas de ligacao a adrenomedulina
WO2004075838A3 (fr) Methodes et compositions pour le traitement du syndrome d’aspiration meconiale
WO2003093313A3 (fr) Antagonistes d'interaction du facteur viii avec une proteine de recepteur de lipoproteine de faible densite
ATE495751T1 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
DE60036122D1 (de) Verwendung von eplerenon zur behandlung von restenose
HUP0301804A2 (hu) Antitrombotikus ágensek
Hansen et al. Target-mediated clearance and bio-distribution of a monoclonal antibody against the Kunitz–type protease inhibitor 2 domain of tissue factor pathway inhibitor
Gorkun et al. Interactions mediated by the N-terminus of fibrinogen's Bβ chain
EP1334983A3 (fr) Anticorps monoclonal inhibiteur, dirigé contre la protéase activant le facteur de coagulation VII
Astermark et al. Antibodies to factor VIIa in patients with haemophilia and high‐responding inhibitors
DE59909356D1 (de) Pharmazeutische präparation, enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen
DE60128084D1 (de) Verwendung von inaktives cln2 proenzym zur behandlung von lincl